These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 1133681)

  • 1. Bioavailability and pharmacokinetics of prednisone in humans.
    Disanto AR; Desante KA
    J Pharm Sci; 1975 Jan; 64(1):109-12. PubMed ID: 1133681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo availability of commercial prednisone tablets.
    Sullivan TJ; Sakmar E; Albert KS; Blair DC; Wagner JG
    J Pharm Sci; 1975 Oct; 64(10):1723-5. PubMed ID: 1102660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of food on the bioavailability of prednisone.
    Tembo AV; Sakmar E; Hallmark MR; Weidler DJ; Wagner JG
    J Clin Pharmacol; 1976; 16(11-12):620-4. PubMed ID: 791973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioavailability assessment of a liquid prednisone preparation.
    Georgitis JW; Flesher KA; Szefler SJ
    J Allergy Clin Immunol; 1982 Oct; 70(4):243-7. PubMed ID: 7119300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative serum prednisone and prednisolone concentrations following prednisone or prednisolone administration to beagle dogs.
    Colburn WA; Sibley CR; Buller RH
    J Pharm Sci; 1976 Jul; 65(7):997-1001. PubMed ID: 957135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prednisone for chronic active liver disease: pharmacokinetics, including conversion to prednisolone.
    Schalm SW; Summerskill WH; Go VL
    Gastroenterology; 1977 May; 72(5 Pt 1):910-3. PubMed ID: 849821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo bioequivalence of commercial prednisone tablets.
    Francisco GE; Honigberg IL; Stewart JT; Kotzan JA; Brown WJ; Schary WL; Pelsor FR; Shah VP
    Biopharm Drug Dispos; 1984; 5(4):335-44. PubMed ID: 6525441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prednisone and prednisolone bioavailability in renal transplant patients.
    Gambertoglio JG; Frey FJ; Holford NH; Birnbaum JL; Lizak PS; Vincenti F; Feduska NJ; Salvatierra O; Amend WJ
    Kidney Int; 1982 Apr; 21(4):621-6. PubMed ID: 7047863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distribution and metabolism of prednisone in mice, dogs, and monkeys.
    El Dareer SM; Struck RF; White VM; Mellett LB; Hill DL
    Cancer Treat Rep; 1977 Oct; 61(7):1279-89. PubMed ID: 412589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioavailability and reversible metabolism of prednisone and prednisolone in man.
    Garg V; Jusko WJ
    Biopharm Drug Dispos; 1994 Mar; 15(2):163-72. PubMed ID: 8011967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of effect of sucralfate on prednisone bioavailability.
    Gambertoglio JG; Romac DR; Yong CL; Birnbaum J; Lizak P; Amend WJ
    Am J Gastroenterol; 1987 Jan; 82(1):42-5. PubMed ID: 3799579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Removal of prednisone and prednisolone by plasma exchange.
    Stigelman WH; Henry DH; Talbert RL; Townsend RJ
    Clin Pharm; 1984; 3(4):402-7. PubMed ID: 6467876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relative bioavailability of prednisone and prednisolone in man.
    Tse FL; Welling PG
    J Pharm Pharmacol; 1979 Jul; 31(7):492-3. PubMed ID: 38330
    [No Abstract]   [Full Text] [Related]  

  • 14. Prednisone or prednisolone for the treatment of chronic active hepatitis? A comparison of plasma availability.
    Davis M; Williams R; Chakraborty J; English J; Marks V; Ideo G; Tempini S
    Br J Clin Pharmacol; 1978 Jun; 5(6):501-5. PubMed ID: 656293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetics and interconversion of prednisolone and prednisone studied with new radioimmunogassays.
    Meikle AW; Weed JA; Tyler FH
    J Clin Endocrinol Metab; 1975 Oct; 41(4):717-21. PubMed ID: 1176582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of smoking on prednisone, prednisolone, and dexamethasone pharmacokinetics.
    Rose JQ; Yurchak AM; Meikle AW; Jusko WJ
    J Pharmacokinet Biopharm; 1981 Feb; 9(1):1-14. PubMed ID: 7229914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impaired conversion of prednisone to prednisolone in patients with liver cirrhosis.
    Madsbad S; Bjerregaard B; Henriksen JH; Juhl E; Kehlet H
    Gut; 1980 Jan; 21(1):52-6. PubMed ID: 7364321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioavailability of tolazamide from tablets: comparison of in vitro and in vivo results.
    Welling PG; Patel RB; Patel UR; Gillespie WR; Craig WA; Albert KS
    J Pharm Sci; 1982 Nov; 71(11):1259-63. PubMed ID: 7175719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased bioavailability of prednisone due to antacids in patients with chronic active liver disease and in healthy volunteers.
    Uribe M; Casian C; Rojas S; Sierra JG; Go VL
    Gastroenterology; 1981 Apr; 80(4):661-5. PubMed ID: 7202937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of prednisone and its metabolite prednisolone in children with nephrotic syndrome during the active phase and in remission.
    Gatti G; Perucca E; Frigo GM; Notarangelo LD; Barberis L; Martini A
    Br J Clin Pharmacol; 1984 Apr; 17(4):423-31. PubMed ID: 6721988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.